December 15, 2025
1 min read

Adia Nutrition Inc. Announces IRB Approval from BeyondBound for Adia Med’s Autism Clinical Study

Winter Park, Florida–(Newsfile Corp. – December 15, 2025) – Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its Adia Med subsidiary, today announced that the independent Institutional Review Board (IRB) BeyondBound has approved the company’s patent-pending clinical study protocol focused on Autism Spectrum Disorder (ASD).IRB Approval EmailTo view an enhanced version of this graphic, please…

Leave a Reply

Your email address will not be published.

Previous Story

Dr Lewis Nutrition

Next Story

Free pass or failing grade for saturated fats? Review sets off scientific and political debate

Previous Story

Dr Lewis Nutrition

Next Story

Free pass or failing grade for saturated fats? Review sets off scientific and political debate

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader

STAT+: A new attack on AMA’s billing codes

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Brain
Go toTop